AROMA-BIT
23.7.2019 03:32:07 CEST | Business Wire | Press release
Aroma Bit launched a new subsidiary to develop the next generation smell sensor based on silicon CMOS sensor substrate that are ultra-compact, high resolution and low cost. The technology is realized by applying Aroma Bit developed smell sensor receptor membrane technology to ultra-sensitive silicon CMOS based ion imaging sensor technology developed by professor Kazuaki Sawada at Toyohashi University of Technology and associated companies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190722005004/en/
Aroma Bit: http://www.aromabit.com
Realizing smartphone embeddable smell sensor with dog nose equivalent ultra-high resolution smell sensor on only 1 millimeter square silicon die size
Aroma Bit has developed and are currently selling a compact smell sensor that employs QCM or Quartz Crystal Microbalance type sensor substrate, which demonstrates ultra-high sensitivity in the sensor market. However, further size reduction, cost reduction to meet high volume application market, such as smartphone, was challenging with conventional QCM type smell sensor.
With the newly developed silicon CMOS type smell sensor, ultra-compact, high smell resolution and low cost can be realized, to be embedded to system such as smartphone or IoT devices. For instance, it is expected that resolution equivalent to dog nose’s resolution (roughly 1,200 receptors) within 1mm die size can be achieved using the new type of sensor substrate.
With new addition of sensor substrate technology, Aroma Bit now holds two types of sensor substrate technology line up: (1) conventional and yet ultra-high sensitivity QCM type sensor substrate technology, and (2) ultra-high resolution, ultra-compact, low cost silicon CMOS type sensor substrate technology. Combined, highly competitive sensor technology portfolio is realized in two key performance for smell sensor, namely, sensor sensitivity and smell resolution. As a result, the addition of the new sensor is expected to further enhances Aroma Bit’s technology competitive advantage against its competitors in the compact smell sensor space.
Aroma Bit is currently also accelerating its development of digital smell database or smell big-data based on its hardware competitive advantage. Sensor hardware and smell database together, Aroma Bit is committed to retain its top-position in growing digital olfactory market, thereby realizing Aroma Bit’s vision “to realize a better world by visualizing the world of smell/aroma through odor imaging technology.”
New subsidiary certified as the first Toyohashi University of Technology University- Launched Venture Company
The new developed subsidiary, Aroma Bit Silicon Sensor Technology, Inc., is certified as the first Toyohashi University of Technology certified University-Launch Venture Company.
While University-Launched Venture company is on the rise in Japan, there is limited successful case leading to industrialization, due to factors such as lack of intellectual property conflict among large companies interest, skill set mismatch on researcher as entrepreneurs, among others.
In this particular Industry-academia collaboration case, the chance to commercialize technology is expected to increase by assigning venture company a role to drive business development of the technology developed jointly with university.
Background:
Aroma Bit succeeded in developing next generation smell sensor based on silicon CMOS sensor substrate that are ultra-compact and high resolution by applying Aroma Bit developed smell sensor receptor membrane technology to ultra-sensitive silicon CMOS based ion imaging sensor technology developed by professor Kazuaki Sawada at Toyohashi University of Technology.
In 2017, Toyohashi Technology of University, Toyohashi Sensor Kyogikai Corporation, Hamamatsu Photonics K.K., Toho Technology Corporation, Nippon Chemi-con Corporation and Aroma Bit together formed private Consortium COSCo (CMOS Odor Sensor Consortium). In 2018, COSCo consortium released working prototypes such as Kaori-Camera (Aroma Camera) and i-sniffer.
In the interest to aggregate the achievement from COSCo consortium and further accelerate development and industrialization, Aroma Bit Silicon Sensor Technology, Inc. (Hereafter, “ABSST”) is founded as Aroma Bit’s subsidiary.
Going forward, ABSST is committed to develop the silicon CMOS type next generation smell sensor that are ultra-high resolution, ultra-compact and low-cost embeddable to smartphone and IoT Devices.
New Subsidiary Company Profile |
|
Name of company: |
Aroma Bit Silicon Sensor Technology Inc. (ABSST) |
Date of Registration: |
June 28th, 2019 |
Paid-in-Capital: |
10 Million JPY [Aroma Bit, Inc. Subsidiary] |
Business Profile: |
Planning, Development, Manufacturing and Sales of silicon CMOS based next generation smell, gas sensor, and other related business |
Representative Management: |
Representative Director & CEO Shunichiro Kuroki [Current Representative Director & CEO of Aroma Bit, Inc.] |
Address: |
E205 KSP 3-2-1 Sakado, Takatsu-ku, Kawasaki-city, Kanagawa 213-0012 [Aroma Bit Kawasaki Lab] |
Corporate URL: |
|
Contact: |
Email: info@aromabitsst.com
|
About Aroma Bit |
Aroma Bit develops, produces and sells electronic equipments and systems including compact odor imaging sensors. |
[Corporate summary] |
|
Name: |
Aroma Bit, Inc. |
Address: |
Sagami Building 2F 7-13-6 Ginza, Chuo-ku, Tokyo |
Representative: |
Representative Director & CEO Sunichiro Kuroki |
Established: |
February, 2014 |
Business: |
- Development, Production and Sales of electronic equipments and systems including compact odor imaging sensors. |
- Development, Production and Sales of innovative services using the Sensor products. |
|
|
- Other business related to the above. |
Corporate URL: |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20190722005004/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Real Chemistry Announces New Asia Pacific Hub with Acquisition of Spurwing Communications in Singapore7.7.2026 01:00:00 CEST | Press release
Expanded footprint advances the company’s global strategy in key growth region for healthcare and pharma brands Real Chemistry, a global leader in AI- and insights-driven healthcare communications, today announced the acquisition of Spurwing Communications, establishing the company’s first Asia Pacific (APAC) strategic hub in Singapore. This milestone strengthens Real Chemistry’s global strategy and presence in APAC, enhancing its ability to support healthcare organizations. Combining deep market expertise with globally integrated capabilities across analytics, medical communications, advertising and strategic communications, the company is well positioned to deliver more connected, local insight-driven support — ultimately helping clients better reach and engage healthcare professionals, patients and caregivers across the region. “APAC is fast becoming one of the most dynamic and strategically important regions for healthcare innovation and access to life-improving therapies,” said Ka
Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 22:04:00 CEST | Press release
- Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex’s portfolio - - PALSONIFY®, Crinetics’ recently launched, first and only, once-daily oral therapy for adults with acromegaly has demonstrated strong and growing early uptake - - Atumelnant, a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist in Phase 3 development for congenital adrenal hyperplasia (CAH), has shown unique and transformative potential to both normalize androgen levels and enable management of patients with physiologic levels of glucocorticoids, the true goal of CAH management; atumelnant has also demonstrated therapeutic potential in patients with Cushing’s syndrome - - Acquisition adds to Vertex’s innovation pipeline, accelerates Vertex’s revenue growth and enhances long-term earnings profile - - Vertex to host investor call today, July 6 at 4:30 p.m. ET - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and C
Ciauru Wins the Second Edition of the Reply AI Music Contest, the International Competition Dedicated to Experimentation Across AI, Music and Live Performance6.7.2026 20:30:00 CEST | Press release
The winner was announced on the Kappa FuturFestival stage, following the performances of the five finalists selected by the international jury.German duo PARAFRAME & Avis Vox received the special Reply AI Studios Grand Prix award. The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706007611/en/ The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival First place went to Ciauru, the stag
Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 15:00:00 CEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda
Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 15:00:00 CEST | Press release
Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
